Clinical Trials in Yekaterinburg, Russia

32 recruiting

Showing 120 of 30 trials

Recruiting

ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia

AsthmaChronic Rhinosinusitis With Nasal Polyps (CRSwNP)
AstraZeneca110 enrolled9 locationsNCT07399665
Recruiting

Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study

Uncontrolled Asthma
AstraZeneca9,000 enrolled47 locationsNCT06521229
Recruiting

Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia

Breast Cancer
Novartis Pharmaceuticals2,766 enrolled37 locationsNCT06930859
Recruiting

Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia

Neurofibromatosis
AstraZeneca200 enrolled13 locationsNCT07088991
Recruiting

Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)

Severe Asthma
AstraZeneca5,000 enrolled37 locationsNCT06472310
Recruiting
Phase 3

The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients

RhinosinusitisRhinosinusitis Acute
Materia Medica Holding552 enrolled44 locationsNCT06901297
Recruiting
Phase 3

Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years

Acute Respiratory Viral Infection
Materia Medica Holding374 enrolled35 locationsNCT06715891
Recruiting
Phase 4

Secukinumab Open Label Roll-over Extension Protocol

Autoimmunity, Inflammation
Novartis Pharmaceuticals1,000 enrolled167 locationsNCT04638647
Recruiting

Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration

Prostate Cancer
AstraZeneca400 enrolled18 locationsNCT07052578
Recruiting

An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation

Endometrial Cancer
AstraZeneca500 enrolled21 locationsNCT07041606
Recruiting

TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

Bladder Cancer
AstraZeneca600 enrolled19 locationsNCT07038928
Recruiting
Phase 3

An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment

Multiple Sclerosis
Hoffmann-La Roche500 enrolled44 locationsNCT06675955
Recruiting
Phase 3

Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children

Cough
Materia Medica Holding264 enrolled30 locationsNCT07171099
Recruiting

CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia

Unresectable /Inoperable Locally Advanced (Stage II-III) NSCLC and Locally Advanced LS-SCLC (Stage I-III)
AstraZeneca2,000 enrolled41 locationsNCT05887011
Recruiting
Phase 3

Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug

InfectionsMeningococcal
NPO Petrovax240 enrolled17 locationsNCT06834100
Recruiting

Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation

Prostate Cancer
AstraZeneca400 enrolled17 locationsNCT07146113
Recruiting

Study of Patient With Frequent COPD Exacerbations

Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca2,000 enrolled6 locationsNCT07221981
Recruiting
Phase 2

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

Merck Sharp & Dohme LLC40 enrolled26 locationsNCT04665037
Recruiting
Phase 2

BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer

Biocad124 enrolled47 locationsNCT07108309
Recruiting

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals2,382 enrolled20 locationsNCT06858332